INTRODUCTION
The molecular events underlying neurodegeneration of Alzheimer's disease are not established, but it has been suggested that an excitotoxic mechanism mediated by excessive extracellular glutamate may be a contributory factor, and more recently the neurotoxicity of aggregated /-amyloid has received much attention (for review see [1] ). In support of an excitotoxic mechanism, Mattson and colleagues have reported that glutamate and fl-amyloid act synergistically to cause neuronal death in vitro and that this cell death is preceded by an increase in perikaryal tau immunoreactivity, which is also produced by treatment of neurons with colchicine [2, 3] ; these changes in perikaryal tau were suggested to mimic those observed in neurofibrillary tanglebearing neurons in Alzheimer's disease [2] . Since at least many degenerating neurons in the Alzheimer's-disease brain exhibit a characteristic cytoskeletal pathology, particularly hyperphosphorylated paired helical filament (PHF) tau, we set out to investigate whether in cultured neurons neurotoxicity induced by glutamate, colchicine and 8-amyloid produced changes in the phosphorylation state of tau that may parallel those occurring in Alzheimer's disease. SMI3 10, all additionally known to recognize tau in a phosphorylation-dependent manner, also demonstrated that glutamate and colchicine treatments of the cultures induced a dephosphorylation of tau. We also showed immunocytochemically that there is an increase in tau immunoreactivity in neuronal perikarya in response to glutamate and colchicine treatment, and this occurs concomitantly with the dephosphorylation of tau. Treatment of the primary rat cortical neuronal cultures with i25.35-amyloid peptide, under conditions which induce neuronal degeneration, did not induce a change in tau phosphorylation, and failed to act synergistically with glutamate to produce an increase in dephosphorylation of tau over that produced by glutamate treatment alone. These findings demonstrate that glutamate and colchicine induce tau dephosphorylation, as opposed to increased tau phosphorylation, which would be more indicative of Alzheimer-type neurodegeneration.
The microtubule-associated phosphoprotein tau is a major constituent of PHF, which constitute neurofibrillary tangles, a pathological hallmark of Alzheimer's disease [4, 5] . PHF-tau differs from tau isolated from normal adult human brain in that it is resolved on SDS/PAGE as three to four bands of apparent molecular mass 60-68 kDa, instead of the six or more bands of apparent molecular masses between 55 and 62 kDa that are characteristic of normal adult brain tau [6] [7] [8] [9] [10] ; PHF-tau can be induced to migrate like normal tau by treatment with alkaline phosphatase, suggesting that it is excessively phosphorylated [9] [10] [11] . PHF-tau has also been shown to be hyperphosphorylated through the use of a number of monoclonal antibodies that recognize specific phosphorylated epitopes and discriminate normal adult brain tau from PHF-tau [12, 13] . By contrast, tau extracted from foetal brain comprises a single isoform that corresponds to the shortest adult brain tau species, and a fraction of this foetal tau is in an elevated state of phosphorylation, resembling the phosphorylation state of PHF-tau [14] [15] [16] .
The majority of investigations of immunocytochemical changes in tau in response to excitotoxic levels of glutamate and other agents have employed only a limited number of antibodies 942 D. R. Davis and others more recently been demonstrated to discriminate control adult brain tau from the more highly phosphorylated PHF-tau. It has only recently been realized that the phosphorylation state of a proportion of foetal tau is elevated compared with control adult brain tau, and that this fraction of foetal tau already resembles PHF-tau, as assessed by application of discriminatory antibodies [14] [15] [16] [17] [18] . In the present study we have used a panel of such monoclonal antibodies and taken account of the known higher level of phosphorylation of some of the foetal tau to re-examine the effects of toxic levels of glutamate, colchicine and f8-amyloid on tau phosphorylation in rat cortical neurons in primary culture.
We report here that a proportion of tau in cultured rat cortical neurons normally has a higher level of phosphorylation than control adult brain tau, and is therefore similar to foetal tau in vivo and to PHF-tau from Alzheimer's-disease brain, and that dephosphorylation of this tau occurs after treatment with toxic levels of glutamate or colchicine, but before cell death, as assessed by release of lactate dehydrogenase. Concomitant with dephosphorylation, perikaryal tau immunoreactivity is increased, as assessed by immunocytochemical analyses of the cultures. These changes in tau phosphorylation in response to glutamate and colchicine treatment are opposite to what would be expected if they triggered the formation of PHF. Furthermore, we were unable to induce any changes in tau phosphorylation by exposing cultures to toxic doses of,-amyloid peptide in either the absence or the presence of glutamate, until there was obvious cell death, when the loss of tau immunoreactivity was most likely due to non-specific effects, e.g. release of lysosomal hydrolases.
MATERIALS AND METHODS Antibodies
The preparation of the affinity-purified polyclonal antibody to human tau, 8073, and polyclonal antibody to bovine tau, B19, that recognize all tau isoforms independently of their phosphorylation states, have previously been described [8, 19] . The mouse monoclonal antibody, Tau. 1, that recognizes a dephosphorylated epitope in normal tau [20] was generously given by Dr. L. I. Binder (University of Alabama, Birmingham, AL, U.S.A.). The monoclonal antibody, AT8 [21] , that recognizes a phosphorylated epitope (Ser-202) on PHF-tau and that corresponds to the Tau. 1 epitope when unphosphorylated (Ser-199 and Ser-202) was a gift from Innogenetics Ltd., Zwijndrecht, Belgium. Antiserum TP70, raised to a synthetic C-terminal tau peptide, has been previously described [12] . The TP007 antiserum was raised to a synthetic peptide corresponding to the 16 most N-terminal residues of human tau that are present in all tau isoforms. RT97, 8D8, SMI3 1 and SMI3 10 are monoclonal antibodies that recognize phosphorylated neurofilament and PHF-tau [12, 13, [22] [23] [24] .
Primary neuronal culture
Embryonic-rat (E17) cortices were dissected into Hanks balanced salt solution (HBSS; Gibco, Paisley, Scotland, U.K.), cleaned of meninges and chopped. HBSS was removed by aspiration and the tissue was incubated in HBSS containing 0.05% (w/v) trypsin (Sigma, Poole, Dorset, U.K.) at 37°C for 15 min. The trypsin solution was then removed by aspiration and replaced with HBSS containing 8 mM MgCl2, 0.002% (w/v) DNase, 10 Determination of neurotoxicity LDH was assessed in culture media by using a LDH isoenzyme assay kit (Sigma) as an indication of neuronal cell damage [25] . Samples ofmedia in incubation buffer were mixed with Cellustain reagent [10 parts of NAD+, 85 parts of lithium L(+)-lactate, 5 parts of Nitro Blue Tetrazolium and 0.1 part of phenazine methosulphate] and incubated at room temperature in the dark for up to 30 min. The A550 of the resulting colour was measured. The change in A55 measured in cultures treated with glutamate for 24 h, in which all neurons were dead, was taken as 100 % LDH release. The means of six measurements from each treatment group were compared with the control group by Student's t test. 
TBS-T-M), followed by further washing in TBS-T and incubation
for 1 h in streptavidin-alkaline phosphatase (Amersham; diluted 1: 3000 in TBS-T-M). After final washes in TBS-T, blots were developed by using an alkaline phosphatase conjugate substrate kit (Bio-Rad, Hemel Hempstead, Herts., U.K.). Before separation by SDS/PAGE, the protein content of each sample was determined, by using a dot-blot stained with Coomassie Blue and so that loading on to the electrophoresis gels could be normalized for total protein. (1 psM) for up to 6 h and labelled with an affinity-purified polyclonal antibody to human tau, 8073, and the monoclonal antibody, Tau. 1, as indicated. As we described previously for foetal tau in vivo, the major tau species run either as a broad band or as a closely migrating and poorly resolved doublet of approx. 48 kDa (arrows), that is labelled by the polyclonal antibody, but only the faster-migrating species of the doublet (or portion of the broad band) was labelled by Tau.1 [14] . However, after incubation for 30 min with glutamate, two lower-molecular-mass bands (arrowheads) were recognized by 8073 also observed a similar pattern of LDH release after colchicine treatment of the primary neuronal cultures (results not shown). Figure 2 shows Western blots of total cell-lysate protein from 10-day-old cultures that were treated with glutamate (1 mM) for zero (control) or 6 h, and have been probed with a panel of antibodies. TP70 (Figure 2c ) and TP007 (Figure 2d ) (polyclonal antibodies that recognize the C-and N-termini oftau respectively) both labelled the initial tau broad band/doublet (arrows) and the same strongly immunoreactive faster-migrating species (arrowheads) as recognized by 8073 (Figure 2a) and Tau. 1 (Figure 2b ) that appear after glutamate treatment of the cultures. On some blots, an additional higher-molecular-mass tau species of approx. 55-57 kDa was recognized by the polyclonal antibodies TP70 and TP007 and the monoclonal neurofilament antibody 8D8. This probably corresponds to a longer tau isoform and can also be detected in 3-day-postnatal rat brain [14] . The labelling of the faster-migrating tau species (arrowheads) by antibodies to both extremities of the tau polypeptide demonstrates that these principal faster-migrating species are not the products of proteolysis, but rather are due to dephosphorylation of tau; these species are also hardly labelled, if at all, by the phosphate-dependent monoclonal antibodies (Figures 2e-2i) . Similar dephosphorylation in vitro of neuronal tau in cell lysates by alkaline phosphatase in the presence of a cocktail of protease inhibitors also demonstrated that the faster-migrating species were the product of dephosphorylation and not proteolysis (see below and Figure 4) . The additional and apparently smaller species than those indicated by arrowheads that were present after glutamate treatment and recognized by Tau.1 (Figure 2b ) and TP007 (Figure 2d ), are probably tau degradation products, because they were not recognized by the C-terminal antibody TP70 (Figure 2c) .
The monoclonal antibodies AT8, 8D8, RT97, SMI31 and SMI310 (Figures 2e-2i respectively) , all of which recognize phosphorylated tau epitopes, and which label only the slowermigrating species of the broad band/doublet of tau [14] , showed a decrease in intensity of labelling of this tau species after glutamate treatment of cultures for 6 h and, indeed, the labelling by AT8 was abolished. It was with these phosphate-dependent monoclonal antibodies that two differently phosphorylated species of tau were most clearly observed, since in untreated cultures they consistently labelled a narrow and the most slowmigrating fraction of the broad band/doublet of tau ( Figures  2e-2i) . Conversely, Tau. 1 showed an increase in staining intensity of the faster-migrating component of the broad band/doublet after 6 h of glutamate treatment (Figure 2b ). These results suggest that a significant proportion of the tau in primary rat cortical cultures is normally highly phosphorylated and becomes dephosphorylated after glutamate treatment. Although neuronal death occurs, since LDH is released, this process is gradual, as has been demonstrated by others [27] [28] [29] [30] , and the dephosphorylation of tau commences before this lytic stage (Figure 1 ), but is more evident after 6 h of treatment. The monoclonal antibodies 8D8, RT97, SMI31 and SMI310 (which are all neurofilament antibodies) all recognized a highmolecular-mass band, corresponding to neurofilament protein NF-H (Figure 2, asterisk) , in both control and treated samples. After glutamate stimulation, a second high-molecular-mass band was recognized by all of these neurofilament antibodies that may correspond to neurofilament protein NF-M or a degradation product of NF-H. In addition, these neurofilament monoclonal antibodies variably labelled to different intensities several other species throughout the molecular-mass range that may be degradation products of neurofilaments. On the other hand, as all of these antibodies selectively recognize phosphorylated epitopes, glutamate treatment of the cultures, conversely to its effects on tau, may induce phosphorylation of some proteins that are then cross-reactive with monoclonal antibodies against phosphorylated NF-H. Indeed, 8D8 staining of a band in the NF-M region is strongly increased by glutamate treatment, and since the control sample does not contain a longer species of comparable immunoreactivity, it would appear that this molecular-mass band is most likely due to an increase in neurofilament phosphorylation.
Coichicine-Induced dephosphorylation of tau in primary rat cortical neuronal cultures Figure 3 Colchicine-induced dephosphorylation of tau In primary neuronal cultures (a-Western blots of total cell-lysate proteins from control primary 6-day-old rat cortical cultures (lanes 1) and 6-day-old cultures treated with colchicine (1 1uM) for 6 h (lanes 2), and incubated with (a) 8073, (b) Tau.1, (c) TP70, (d) TPOO7, (e) AT8 and (f) 8D8; (g) and (h) are Western blots of total cell-lysate proteins extracted from 10-day cultures incubated with (g) AT8 and (h) 8D8.
Arrows indicate the positions of the major tau broad band/doublet, and arrowheads indicate the positions of the two intact less phosphorylated and faster-migrating tau species. As in Figure 2 , a minor tau-positive species (approx. 57 kDa) indicates the presence of a longer tau isoform; the presence of this species is most marked with TP70. TP70 probably also labels MAP2C (asterisk), and this too is shifted to faster-migrating forms after coichicine treatment. Numbers to the right of the Figure represent approximate molecular masses (kDa). Figure 3 ) and immunocytochemically (results not shown). The polyclonal antibody 8073 showed the generation of increased amounts of lower-molecular-mass species (arrowheads) on Western blots (Figure 3a) , after treatment of 6-day cortical cultures with 1 ,uM colchicine for 6 h. Tau. 1 showed the appearance of two faster-migrating tau species (arrowheads) after colchicine treatment (Figure 3b ), whereas AT8 failed to label tau after the same treatment in both 6-and 10-day cultures ( Figures  3e and 3g respectively). After treatment with colchicine, the monoclonal anti-neurofilament antibody 8D8 showed a modest decrease in intensity of labelling on 6-day cultures and abolition of labelling of 10-day cultures (Figures 3f and 3h respectively) . Again, these changes were not the result of tau proteolytic degradation, since the principal faster-migrating bands (arrowheads) were both labelled by the antibodies TP70 and TP007 (C- and N-terminal anti-tau polyclonal antibodies, respectively) ( Figures 3c and 3d respectively), although additional weakly taupositive bands migrating faster than those indicated by arrowheads probably are degradation products. The higher-molecularmass band recognized by the polyclonal antibody TP70 (asterisk) is probably due to cross-reactivity with the microtubule-associated protein MAP2C, which is also shifted to a faster-migrating species after colchicine treatment, tau and MAP2C having a high degree of similarity at their C-termini [31] . The higher-molecularmass tau species also recognized by TP70 (approx. 57 kDa) is referred to above.
Dephosphorylation in vitro of tau from primary rat cortical neuronal cultures In order to confirm further that the observed effects of glutamate and colchicine on tau immunoreactivity were indeed due to dephosphorylation of tau, a heat-stable protein preparation from 10-day primary cortical cultures was treated with alkaline phosphatase in the presence of a cocktail of protease inhibitors (see the Materials and methods section). After enzyme treatment, a proportion of the tau had an increased electrophoretic mobility (Figures 4a-4c , arrowhead) and showed a total loss of labelling with the phosphorylation-dependent antibody AT8 (Figure 4d ). This dephosphorylation was similar to, although not identical with, that seen after glutamate and colchicine treatments of the neuronal cultures. Not all of the tau was dephosphorylated by alkaline phosphatase treatment in vitro, and we have found it difficult to achieve complete dephosphorylation. The N-and Cterminal antibodies TP70 and TP007 also labelled this dephosphorylated tau (Figures 4b and 4c) , demonstrating that this faster-migrating species was the result of dephosphorylation and not degradation of tau. Tau. 1 also labelled small amounts of additional faster-migrating species after alkaline phosphatase treatment, which probably were the result of proteolysis ( Figure   4a ). cortical neurons was investigated by immunocytochemical labelling in situ with polyclonal antiserum B19 and the monoclonal antibodies AT8 and Tau. 1. In 10-day-old control cortical cultures, the polyclonal antibody B19 labelled axons and neuronal cell bodies ( Figure 5a) ; the Tau. 1 monoclonal antibody labelled axons with variable intensity, some long axons being strongly labelled, but this antibody labelled the perikarya only weakly (Figure 5c ). AT8 displayed labelling very similar to that of B19, i.e. a labelling of cell bodies and axons ( Figure Se) . A significant number of neurons also showed a labelling of dendrites or the proximal part of dendrites, with both B19 and AT8 (Figures 5a and 5e ). Glutamate treatment (1 mM for 6 h) of 10-day-old cultured cortical neurons induced marked changes in the tau immunoreactivity. The polyclonal B19 antibody still labelled axons and perikarya, but the tau immunoreactivity in perikarya was clearly increased in a significant proportion of neurons (Figure 5b ). Tau. 1 strongly labelled many neuronal perikarya (Figure 5d ), while still demonstrating immunoreactivity with axons. Contrary to this, AT8 immunoreactivity was strongly decreased throughout glutamatetreated neurons (Figure 5f ).
Immunocytochemistry of primary rat cortical neuronal cultures
Immunocytochemical labelling of 6-day-old control cortical neurons with the polyclonal antibody B19 and monoclonal antibodies Tau. 1 and AT8 was similar to that described above for the 10-day-old control cultures (results not shown). In colchicinetreated (1 ,tM for 6 h) 6-day-old neuronal cultures, the change in immunoreactivity with the polyclonal antibody B19 and monoclonal antibodies Tau.1 and AT8 was similar to that seen after glutamate treatment, in that B19 and Tau. 1 both showed an increase in labelling of many neuronal perikarya and AT8 showed a decrease in neuronal immunoreactivity in a significant proportion of neurons (results not shown).
Effect of okadale acid on glutamate-induced tau dephospherylatlon
In order to investigate potential phosphatase involvement in the glutamate-induced dephosphorylation of neuronal tau, we studied the effects of okadaic acid on this process. However, we found that 250 nM okadaic acid alone further slightly decreased the mobility of tau after 1 h of treatment, as assessed with the polyclonal antibody TP70 (Figure 6a, lane 4) , and the intensity of staining of tau by monoclonal antibody Tau. after 1 h of okadaic acid treatment was decreased, indicating increased phosphorylation at Ser-199/202 (Figure 6b ). Both of these changes are consistent with additional overall phosphorylation of the tau. When cells were treated with both okadaic acid and glutamate, then the two effects ofeach agent occurred together. Thus, the two faster-migrating tau species were generated and the slowestmigrating tau band was apparently even further decreased in mobility (Figure 6a, compare lane 1 with lanes 6-9) . However, the staining by monoclonal antibody 8D8 was decreased ( Figure  6c , lane 5). This implies that the effects of okadaic acid treatment are complex, in that it inhibits some phosphatase activity to cause a further decrease in mobility, but it does not inhibit the phosphatase activity responsible for dephosphorylating the 8D8 epitope in these cultures. 8D8 also did not recognize these faster-migrating bands, but labelled the initial broad tau band/doublet less intensely after fl2, 35-amyloid peptide treatment (Figures 7d and 7e respectively) of the cultures. However, this decrease in immunoreactivity with the phosphate-dependent antibodies was not obviously greater than that observed with the polyclonal antibodies, demonstrating that tau degradation rather than dephosphorylation is the predominant response to treatment with f825-35-amyloid peptide.
I8-amyloid failed to
We have tried many different experimental paradigms in order to investigate the effect of fl2, 35 -amyloid on tau phosphorylation in primary neuronal cultures, and the results shown in Figure 7 are typical of the data obtained. [32, 33] , but these studies were over short periods of treatment, and we have been unable to confirm these findings, and the reason for this discrepancy is as yet unclear.
Although the faster-migrating tau component of the broad band/doublet present initially in the cultured neurons, and which is labelled by Tau.1 but not the phosphate-dependent monoclonal antibodies, is clearly less phosphorylated than the slightly slower migrating species, it nevertheless is phosphorylated, since treatment of the cultures with glutamate resulted in the appearance of additional and faster-migrating species (arrowheads in Figures 1-3 ). This was confirmed by the treatment in vitro with alkaline phosphatase of heat-stable tau extracted from the cultures. It is therefore likely that this faster-migrating species of foetal tau is phosphorylated at sites other than those recognized by the panel of available monoclonal antibodies, all of which recognize phosphorylated serine/threonine residues followed by proline, i.e. SP or TP motifs. These extra phosphorylation sites may reside in the C-terminal half of the molecule, since we and others have shown that phosphorylation in vitro of the C-terminal half of recombinant tau by cyclic AMPdependent protein kinase or Ca2+/calmodulin-dependent protein kinase, probably at sites other than SP or TP residues, results in a significant upward shift in mobility of tau [34] [35] [36] [37] [38] [39] .
The dephosphorylation of foetal tau induced by glutamate or colchicine was incomplete, because not all the tau shifted to the fastest-migrating form. Nevertheless, the epitopes recognized by the phosphate-dependent monoclonal antibodies were in some experiments completely dephosphorylated. The mechanism by which glutamate and colchicine induce a dephosphorylation of tau in primary neuronal cultures has yet to be elucidated, but, since both these agents give rise to an increase in perikaryal tau immunoreactivity, it is possible that they share a similar mechanism that might involve a decrease in the number of polymerized microtubules. Glutamate could act by increasing intracellular Ca2+ levels, thus leading to microtubule destabilization and consequently the release of tubulin-bound tau [3, 32, 40] . Direct destabilization of microtubules by colchicine, independently of Ca2l influx, might have the same effect. Phosphorylation appears to regulate the tau-microtubule interaction [41] [42] [43] [44] , and so, if there is a shift from polymerized to unpolymerized tubulin, then dephosphorylation of tau may be a compensatory mechanism to promote microtubule assembly after neurotoxic insult. Sygowski et al. [45] also demonstrated that colchicine treatment of NIH 3T3 fibroblasts expressing transfected tau resulted in the tau becoming less phosphorylated, although not all microtubuledestabilizing agents produced this effect.
The regulation of tau phosphorylation is probably complex, since experiments with okadaic acid treatment of neuronal cultures produced a slight decrease in electrophoretic mobility of tau, and this was still observed when the cultures were treated with a mixture of glutamate and okadaic acid, although under the latter conditions staining by the monoclonal antibody 8D8 was decreased markedly. This implies that inhibition of protein phosphatases PPl and PP2A by okadaic acid causes an electrophoretic-mobility shift, but that these phosphatases do not act on the 8D8 epitope. Indeed, studies in vitro have demonstrated that protein phosphatases PPI, PP2A, PP2B and PP2C can all dephosphorylate tau, but with differential potencies towards individual sites [46] [47] [48] .
Our immunocytochemical results confirm the findings of Mattson and colleagues [3, 40] that both glutamate and colchicine treatment of neurons in primary culture results in increased perikaryal immunoreactivity of tau, but our data also show that accompanied by a decrease in phosphorylation of the protein, consistent with the Western blot analysis (Figures 1, 2 and 3 ). These immunocytochemical changes in the presence of colchicine and glutamate occurred during the course of neuronal degeneration, but were apparently not the consequence of cell death.
This increase in perikaryal tau immunoreactivity in primary neurons treated with glutamate, colchicine or glutamate, in conjunction with ,-amyloid peptides, has previously been suggested to mimic changes observed in neurons containing PHF in Alzheimer's disease, and it was proposed that one mechanism by which ,-amyloid is neurotoxic is by acting synergistically with glutamate [2, 49, 50] . However, the dephosphorylation of tau observed in glutamate-and colchicine-treated primary neurons in the present study is opposite to the increase in phosphorylation that is associated with the conversion of adult brain tau into PHF-tau. We found, however, that l25 35- In conclusion, although the immunocytochemical changes seen in primary neurons treated with glutamate and colchicine superficially mimic those seen in neurons containing PHF in Alzheimer's disease, i.e. an accumulation of tau in neuronal perikarya [51] , this redistribution is associated with a dephosphorylation rather than increased phosphorylation of tau. This dephosphorylation is associated with neuronal degeneration (as assessed by release of LDH), but commences before there is any significant cell lysis. The pattern of phosphorylation changes is thus opposite to that associated with PHF formation in Alzheimer's disease. However, since primary rat cortical neurons do contain a significant proportion of tau in an elevated state of phosphorylation, they thus represent a valuable cellular model for investigating those mechanisms that regulate tau phosphorylation during development, and for identifying candidate phosphatases or kinases that may, nevertheless, be involved in tau phosphorylation in the pathogenesis of Alzheimer's disease.
